Results 161 to 170 of about 931,651 (296)

Medical Microbiology [PDF]

open access: yesJournal of Clinical Pathology, 1984
openaire   +1 more source

Navigating the Post‐BCMA/GPRC5D Landscape: Efficacy of Selinexor, Bortezomib, and Dexamethasone After Sequential Immunotherapy Failure in Penta‐Refractory Multiple Myeloma—A Multicenter Analysis

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT Patients with relapsed/refractory multiple myeloma (RRMM) who are penta‐drug refractory, defined as resistant to two proteasome inhibitors, two immunomodulatory agents, and an anti‐CD38 monoclonal antibody, face a dismal prognosis, particularly after exposure to T‐cell–redirecting therapies.
Maximilian Al‐Bazaz   +22 more
wiley   +1 more source

Correction: Post-vaccination SARS-CoV-2 infections and antibody responses after BNT162b2 in patients with severe obesity: a retrospective cohort study. [PDF]

open access: yesFront Endocrinol (Lausanne)
Kara Z   +8 more
europepmc   +1 more source

Natural History of Chronic Kidney Disease in Sickle Cell Disease

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT Kidney complications, referred to as nephropathy, develop early in sickle cell disease (SCD). In addition to its known morbidity, abundant data show that chronic kidney disease (CKD) is associated with an increased mortality risk in SCD. Increasing evidence suggests that the natural history of SCD nephropathy is progressive. Initial glomerular
Kenneth I. Ataga
wiley   +1 more source

Correction: Global mapping of sexually transmitted Chlamydia trachomatis disease: a systematic review and meta-analysis. [PDF]

open access: yesBMC Infect Dis
Sameni F   +7 more
europepmc   +1 more source

Efficacy and Safety of Subcutaneous Efgartigimod PH20 in Adults With Primary Immune Thrombocytopenia (ADVANCE SC): A Multicenter, Randomized, Double‐Blinded, Placebo‐Controlled, Phase 3 Trial

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT Primary autoimmune thrombocytopenia (ITP) is characterized by thrombocytopenia, bleeding, and reduced health‐related quality of life. In the Phase 3 ADVANCE IV study, intravenous efgartigimod induced significant platelet count responses versus placebo in patients with chronic ITP. ADVANCE SC, a Phase 3, multicenter, randomized, double‐blinded,
Nichola Cooper   +546 more
wiley   +1 more source

Dissecting Pirtobrutinib Resistance in Mantle Cell Lymphoma Through Single‐Cell Multi‐Omics

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT Pirtobrutinib (PBN), a non‐covalent BTK inhibitor, has been approved by the FDA for relapsed/refractory mantle cell lymphoma (MCL); however, resistance to PBN has been observed. To dissect the molecular dynamics driving PBN resistance, we performed integrative single‐cell multi‐omic profiling (scRNA‐seq, scATAC‐seq, and scDNA‐seq) on ...
Fangfang Yan   +10 more
wiley   +1 more source

Student preferences for microbiology laboratory teaching approaches in a problem-based learning curriculum. [PDF]

open access: yesAccess Microbiol
Joji RM   +8 more
europepmc   +1 more source

Safety and Effectiveness of Sutimlimab in Cold Agglutinin Disease: A Real‐World International Experience

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT Sutimlimab is a monoclonal antibody against complement fraction C1s approved for the treatment of hemolytic anemia due to cold agglutinin disease (CAD). Here, we analyzed and report the largest international CAD cohort of sutimlimab‐treated patients ever reported to highlight its safety and effectiveness in the real‐world setting. We accrued a
Bruno Fattizzo   +38 more
wiley   +1 more source

Home - About - Disclaimer - Privacy